Antares Pharma announces LEO Pharma's launch of OTREXUP to dermatologists Antares Pharma announced LEO Pharma’s launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration approved subcutaneous methotrexate product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP is indicated for use in adults who need symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy. OTREXUP is also indicated for adults with severe active rheumatoid arthritis who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents, or children with active polyarticular juvenile idiopathic arthritis. OTREXUP was approved by the FDA in October 2013.
News For ATRS From The Last 14 Days
Check below for free stories on ATRS the last two weeks.